

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): March 26, 2020**

**ORGANOGENESIS HOLDINGS INC.**

(Exact Name of Registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-37906**  
(Commission  
File Number)

**98-1329150**  
(IRS Employer  
Identification No.)

**85 Dan Road**  
**Canton, MA**  
(Address of principal executive offices)

**02021**  
(Zip Code)

**(781) 575-0775**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Registrant's name or former address, if change since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Class A Common Stock, \$0.0001 par value</b>	<b>ORGO</b>	<b>Nasdaq Capital Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.

## Item 1.01 Entry into a Material Definitive Agreement.

On March 26, 2020, Organogenesis Holdings Inc., Organogenesis Inc., and Prime Merger Sub LLC (collectively, the “Borrower”) entered into a Third Amendment to Credit Agreement (the “Third Amendment”) dated and effective as of March 26, 2020 with Silicon Valley Bank (“SVB”), as the Issuing Lender and Swingline Lender, the several other lenders from time to time party thereto (the “Lenders”), and SVB, as administrative agent and collateral agent for the Lenders (the “Administrative Agent”). The Third Amendment amends the Credit Agreement (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), dated as of March 14, 2019, by and among the Company, the Issuing Lender and Swingline Lender, the Lenders and the Administrative Agent, that provides for a term loan (the “Term Loan Facility”) and a revolving credit facility, by:

- Increasing the Term Loan Final Payment (as defined in the Credit Agreement) due upon the Term Loan Maturity Date (as defined in the Credit Agreement) to an amount equal to the original aggregate principal amount of the Term Loan Facility multiplied by 6.50% (from 6.25%).
- Increasing the Prepayment Premium due upon prepayment of the Term Loan Facility as follows: 3.50% (from 3.00%) of the outstanding principal amount of the Term Loan Facility if the prepayment occurs on or prior to the one (1) year anniversary of the closing, 2.50% (from 2.00%) of the outstanding principal amount of the Term Loan Facility if the prepayment occurs after such one (1) year anniversary and prior to the second anniversary of the closing, and 1.50% (from 1.00%) of the outstanding principal amount of the Term Loan Facility if the prepayment occurs after the two (2) year anniversary but prior to the three (3) year anniversary of the closing, and 0.50% (from 0.00%) thereafter.
- Setting the Minimum Trailing Twelve Month Consolidated Revenue (as defined in the Credit Agreement) requirements for the fiscal year ending December 31, 2020, tested quarterly, at the following levels: \$235,000,000 for the trailing twelve months ending March 31, 2020; \$253,000,000 for the trailing twelve months ending June 30, 2020; \$260,000,000 for the trailing twelve months ending September 30, 2020; and \$262,000,000 for the trailing twelve months ending December 31, 2020, with minimum revenue covenant levels for the quarterly periods ending March 31, 2021 and thereafter to be agreed between the Lenders and the Borrower no later than March 31 of each applicable fiscal year.
- Adding a covenant requiring Trailing Twelve Month Non-PurePly Revenue (as defined in the Credit Agreement), tested quarterly beginning with the quarter ended September 30, 2020, at the following levels: \$136,500,000 for the trailing twelve months ended September 30, 2020; and \$145,000,000 for the trailing twelve months ending December 31, 2020, with minimum revenue covenant levels for the quarterly periods ending March 31, 2021 and thereafter to be agreed between the Lenders and the Borrower no later than March 31 of each applicable fiscal year.

The foregoing description of the Third Amendment is only a summary and is qualified in its entirety by reference to the Third Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

## Item 9.01. Financial Statements and Exhibits.

### (d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
10.1	<a href="#"><u>Third Amendment to Credit Agreement dated March 26, 2020 among Organogenesis Holdings Inc., Organogenesis Inc. and Prime Merger Sub, LLC, collectively as borrower, and Silicon Valley Bank, in its capacity as the Issuing Lender and Swingline Lender, Silicon Valley Bank, as Administrative Agent, and Silicon Valley Bank and the other lenders listed therein, collectively as Lenders.</u></a>

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Organogenesis Holdings Inc.

By: /s/ Timothy M. Cunningham

Name: Timothy M. Cunningham

Title: Chief Financial Officer

Date: March 30, 2020

**THIRD AMENDMENT  
TO CREDIT AGREEMENT**

This Third Amendment to Credit Agreement (this “**Amendment**”) dated and effective as of March 26, 2020 (the “**Third Amendment Effective Date**”) by and among **ORGANOGENESIS HOLDINGS INC.**, a Delaware corporation (“**Holdings**”), **ORGANOGENESIS INC.**, a Delaware corporation (“**Organogenesis**”) and **PRIME MERGER SUB, LLC**, a Delaware limited liability company (“**Prime**”, and together with Holdings and Organogenesis, individually and collectively, the “**Borrower**”), the several banks and other financial institutions from time to time party to this Agreement (each a “**Lender**” and, collectively, the “**Lenders**”), **SILICON VALLEY BANK** (“**SVB**”), as the Issuing Lender and the Swingline Lender, and **SVB**, as administrative agent and collateral agent for the Lenders (in such capacities, together with any successors and assigns in such capacity, the “**Administrative Agent**”).

WITNESSETH:

WHEREAS, Borrower, the Administrative Agent, the Issuing Lender and the Swingline Lender are parties to that certain Credit Agreement dated as of March 14, 2019, as amended by that certain First Amendment to Credit Agreement dated as of November 12, 2019, and as further amended by that certain Second Amendment to Credit Agreement dated as of February 13, 2020 (as amended, modified, supplemented or restated and in effect from time to time, the “**Credit Agreement**”);

WHEREAS, the Borrower has requested that the Lenders and the Administrative Agent agree to modify and amend certain terms and conditions of the Credit Agreement to, modify a financial covenant, subject to the terms and conditions contained herein; and

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1. **Capitalized Terms.** All capitalized terms used herein and not otherwise defined shall have the same meaning herein as in the Credit Agreement or in the other Loan Documents referred to in the recitals hereto, as applicable.

2. **Amendments to the Credit Agreement.**

(a) **Definitions.** Section 1.1 of the Credit Agreement is hereby amended by inserting the following new definition in the appropriate alphabetical order:

“**Non-PuraPly Revenue**”: is, as of any date of measurement, all revenues received by Borrower for the applicable calculation period excluding revenues received by Borrower from the sale of Wound Care PuraPly AM and XT and Surgical PuraPly AM and MZ.”

(b) **Definitions.** Section 1.1 of the Credit Agreement is hereby amended by deleting the following term and its existing definition and inserting the following in lieu thereof:

“**Monthly Burn**”: is, as of any date of measurement, (i) Borrower’s average monthly Consolidated Adjusted EBITDA for the three-month period ending as of the date of measurement, less (ii) the Borrower’s average monthly Consolidated Capital Expenditures for the three-month period ending as of the date of measurement, as adjusted for up to \$8,000,000 in one-time expenses related to Borrower’s build out of its facility in Norwood, Massachusetts, as approved by the Required Lenders in their sole discretion; provided, that if the result of clause (i) less clause (ii) is greater than zero, such result shall be deemed to be zero.”

(c) **Final Payment.** Section 2.9(b) of the Credit Agreement is hereby amended by deleting the reference to “6.25%” therein in its entirety and inserting “6.50%” in lieu thereof.

(d) **Prepayment Premium.** Section 2.11(c) of the Credit Agreement is hereby amended in its entirety and the following is inserted in lieu thereof:

“(c) **Prepayment Premium Regarding Term Loans.** No amount of outstanding Term Loans shall be prepaid by the Borrower pursuant to Section 2.11(b) unless the Borrower pays to the Administrative Agent (for the ratable benefit of the Term Lenders), contemporaneously with the prepayment of such Term Loans, (i) the Term Loan Final Payment (if due pursuant to Section 2.9(b)); and (ii) a Term Loan prepayment premium equal to, (A) with respect to any such Term Loan prepayment made during the period commencing on the Closing Date and ending on the first anniversary of the Closing Date, 3.50% of the aggregate amount of the Term Loans so prepaid; (B) with respect to any such Term Loan prepayment made during the period commencing on the first anniversary of the Closing Date and ending prior to the second anniversary of the Closing Date, 2.50% of the aggregate amount of the Term Loans so prepaid; (C) with respect to any such Term Loan prepayment made during the period commencing on the second anniversary of the Closing Date and ending prior to the third anniversary of the Closing Date, 1.50% of the aggregate amount of the Term Loans so prepaid; and (D) with respect to any such Term Loan prepayment made during the period commencing on the third anniversary of the Closing Date and thereafter, 0.50% of the aggregate amount of the Term Loans so prepaid. Any such Term Loan prepayment fee shall be fully earned on the date paid and shall not be refundable for any reason; provided, however, that no prepayment premium shall be required if the existing Term Facility and Revolving Facility are refinanced with a new credit facility that includes both SVB and MidCap as lenders.”

(e) **Financial Condition Covenants.** The Credit Agreement is hereby amended by deleting Section 7.1 in its entirety and inserting the following in lieu thereof:

**“7.1 Financial Condition Covenants.**

(a) Minimum Consolidated Revenue. Permit Consolidated Revenue, measured on a trailing twelve month basis, as of the last day of each quarterly period set forth below to be less than the amount set forth below opposite such quarterly period:

<u>Quarterly Period Ending</u>	<u>Trailing Twelve Month Consolidated Revenue</u>
March 31, 2019	\$ 200,000,000
June 30, 2019	\$ 213,500,000
September 30, 2019	\$ 221,250,000
December 31, 2019	\$ 231,500,000
March 31, 2020	\$ 235,000,000
June 30, 2020	\$ 253,000,000
September 30, 2020	\$ 260,000,000
December 31, 2020	\$ 262,000,000

The minimum Consolidated Revenue requirements for the quarterly periods ending March 31, 2021 and thereafter shall be determined no later than March 31 of each applicable fiscal year, by the Required Lenders, in their reasonable discretion following review of the board-approved Projection delivered pursuant to Section 6.2(c) hereof and consultation with Borrower; provided that such minimum Consolidated Revenue requirements shall in any event not be less than the greater of (i) the actual Consolidated Revenue reported by Borrower for the corresponding fiscal quarter from the prior fiscal year, and (ii) 105% of the Consolidated Revenue threshold for the corresponding fiscal quarter from the prior fiscal year.

(b) Minimum Liquidity. Permit Liquidity at any time, certified monthly by the Borrower as at the last day of any month, to be less than the greater of (i) six (6) months Monthly Burn; and (ii) \$10,000,000.

(c) Non-PuraPly Revenue Covenant. Permit Non-PuraPly Revenue, measured on a trailing twelve month basis, as of the last day of each quarterly period set forth below to be less than the amount set forth below opposite such quarterly period:

<u>Quarterly Period Ending</u>	<u>Trailing Twelve Month Consolidated Revenue</u>
September 30, 2020	\$ 136,500,000
December 31, 2020	\$ 145,000,000

The minimum Non-PuraPly Revenue requirements for the quarterly periods ending March 31, 2021 and thereafter shall be determined no later than March 31 of each applicable fiscal year, by the Required Lenders, in their reasonable discretion following review of the board-approved Projection delivered pursuant to Section 6.2(c) hereof and consultation with Borrower; provided that such minimum Non-PuraPly Revenue requirements shall in any event not be less than the greater of (i) the Non-PuraPly Revenue threshold for the corresponding fiscal quarter from the prior fiscal year, and (ii) 7.5% year-over-year growth, when compared to each corresponding fiscal quarter from the prior fiscal year.”

- (f) **Commitments.** Schedule 1.1A of the Credit Agreement is hereby amended in its entirety and Schedule 1.1A attached hereto is inserted in its place.
3. **Conditions Precedent to Effectiveness.** This Amendment shall not be effective until each of the following conditions precedent have been fulfilled to the satisfaction of the Administrative Agent:
- (a) This Amendment shall have been duly executed and delivered by the respective parties hereto. The Administrative Agent shall have received a fully executed copy hereof and of each other document required hereunder.
  - (b) All necessary consents and approvals to this Amendment shall have been obtained.
  - (c) Prior to and immediately after giving effect to this Amendment, no Default or Event of Default shall have occurred and be continuing.
  - (d) Prior to and immediately after giving effect to this Amendment, the representations and warranties herein and in the Credit Agreement and the other Loan Documents shall be true and correct in all material respects on and as of the date hereof, as though made on such date (except to the extent that such representations and warranties relate solely to an earlier date), in which case such representations and warranties shall have been true and correct in all material respects as of such earlier date.
  - (e) The Lenders and the Administrative Agent shall have received all fees required to be paid, and all expenses for which invoices have been presented (including the reasonable fees and expenses of legal counsel required to be paid hereunder or under any other Loan Document), on or before the Third Amendment Effective Date.

4. Representations and Warranties. Each Loan Party hereby represents and warrants to the Administrative Agent and the Lenders as follows:
- (a) This Amendment is, and each other Loan Document to which it is or will be a party, when executed and delivered by each Loan Party that is a party thereto, will be the legally valid and binding obligation of such Loan Party, enforceable against such Loan Party in accordance with its respective terms, except as enforcement may be limited by equitable principles or by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors' rights generally.
- (b) The representations and warranties set forth in this Amendment, the Credit Agreement, as amended by this Amendment and after giving effect hereto, and the other Loan Documents to which it is a party are true and correct in all material respects on and as of the date hereof, as though made on such date (except to the extent that such representations and warranties relate solely to an earlier date), in which case such representations and warranties shall have been true and correct in all material respects as of such earlier date.
5. Payment of Costs and Fees. The Borrowers shall pay to the Administrative Agent all reasonable costs, out-of-pocket expenses, and fees and charges of every kind in connection with the preparation, negotiation, execution and delivery of this Amendment and any documents and instruments relating hereto (which costs include, without limitation, the reasonable fees and expenses of any attorneys retained by the Administrative Agent or any Lender).
6. Choice of Law. This Amendment and the rights of the parties hereunder, shall be determined under, governed by, and construed in accordance with the laws of the State of New York.
7. Counterpart Execution. This Amendment may be executed in any number of counterparts, all of which when taken together shall constitute one and the same instrument, and any of the parties hereto may execute this Amendment by signing any such counterpart. Delivery of an executed counterpart of this Amendment by telefacsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Amendment. Any party delivering an executed counterpart of this Amendment by telefacsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Amendment, but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Amendment.
8. Effect on Loan Documents.
- (a) The Credit Agreement, as amended hereby, and each of the other Loan Documents shall be and remain in full force and effect in accordance with their respective terms and hereby are ratified and confirmed in all respects. The execution, delivery, and performance of this Amendment shall not operate, except as expressly set forth herein, as a modification or waiver of any right, power, or remedy of the Administrative Agent or any Lender under the Credit Agreement or



any other Loan Document. The consents, modifications and other agreements herein are limited to the specifics hereof (including facts or occurrences on which the same are based), shall not apply with respect to any facts or occurrences other than those on which the same are based, shall not excuse any non-compliance with the Loan Documents, and shall not operate as a consent or waiver to any matter under the Loan Documents. Except for the amendments to the Credit Agreement expressly set forth herein, the Credit Agreement and other Loan Documents shall remain unchanged and in full force and effect. The execution, delivery and performance of this Amendment shall not operate as a waiver of or, except as expressly set forth herein, as an amendment of, any right, power or remedy of the Lenders in effect prior to the date hereof. The amendments, consents, modifications and other agreements set forth herein are limited to the specifics hereof, shall not apply with respect to any facts or occurrences other than those on which the same are based, and except as expressly set forth herein, shall neither excuse any future non-compliance with the Credit Agreement, nor operate as a waiver of any Default or Event of Default. To the extent any terms or provisions of this Amendment conflict with those of the Credit Agreement or other Loan Documents, the terms and provisions of this Amendment shall control.

- (b) To the extent that any terms and conditions in any of the Loan Documents shall contradict or be in conflict with any terms or conditions of the Credit Agreement, after giving effect to this Amendment, such terms and conditions are hereby deemed modified or amended accordingly to reflect the terms and conditions of the Credit Agreement as modified or amended hereby.
- (c) This Amendment is a Loan Document.

9. Entire Agreement. This Amendment, and terms and provisions hereof, the Credit Agreement and the other Loan Documents constitute the entire understanding and agreement between the parties hereto with respect to the subject matter hereof and supersedes any and all prior or contemporaneous amendments or understandings with respect to the subject matter hereof, whether express or implied, oral or written.

10. No Defenses. Each Loan Party hereby absolutely and unconditionally releases and forever discharges the Administrative Agent, each Lender, and any and all participants, parent corporations, subsidiary corporations, affiliated corporations, insurers, indemnitors, successors and assigns thereof, together with all of the present and former directors, officers, agents, attorneys and employees of any of the foregoing (each, a “**Releasee**” and collectively, the “**Releasees**”), from any and all claims, demands or causes of action of any kind, nature or description, whether arising in law or equity or upon contract or tort or under any state or federal law or otherwise (each, a “**Claim**” and collectively, the “**Claims**”), which such Loan Party has had, now has or has made claim to have against any such person for or by reason of any act, omission, matter, cause or thing whatsoever arising from the beginning of time to and including the date of this Amendment which relates directly or indirectly, to the Credit Agreement or any other Loan Document, whether such claims, demands and causes of action are matured or unmatured or known or unknown, except for the duties and obligations set forth in this Amendment and other than with respect to the acts or omissions of any Releasee that a court of competent jurisdiction determines to have resulted from the gross negligence, willful misconduct or bad faith of such Releasee.

11.   Ratification. The Loan Parties hereby restate, ratify and reaffirm each and every term and condition set forth in the Credit Agreement and the Loan Documents effective as of the date hereof and as amended hereby.

12.   Severability. In case any provision in this Amendment shall be invalid, illegal or unenforceable, such provision shall be severable from the remainder of this Amendment and the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

*[Signature pages follow]*

**IN WITNESS WHEREOF**, the parties hereto have caused this Amendment to be duly executed and delivered by their proper and duly authorized officers as of the day and year first above written.

**BORROWER:**

**ORGANOGENESIS HOLDINGS INC.**

By: /s/ Timothy M. Cunningham

Name: Timothy M. Cunningham

Title: CFO

**ORGANOGENESIS INC.**

By: /s/ Timothy M. Cunningham

Name: Timothy M. Cunningham

Title: CFO

**PRIME MERGER SUB, LLC**

By: /s/ Timothy M. Cunningham

Name: Timothy M. Cunningham

Title: CFO

---

**LENDERS:**

**SILICON VALLEY BANK,**

as Issuing Lender, Swingline Lender and as a Lender

By: /s/ Kevin Longo

Name: Kevin Longo

Title: Managing Director

---

**ADMINISTRATIVE AGENT:**

**SILICON VALLEY BANK**

By:  /s/ Kevin Longo

Name: Kevin Longo

Title: Managing Director

---

**ELM 2018-2 TRUST**

as a Lender

By: MidCap Financial Services Capital Management, LLC,  
as Servicer

By: /s/ John O'Dea

Name: John O'Dea

Title: Authorized Signatory

---

**MIDCAP FINANCIAL TRUST**

as a Lender

By: Apollo Capital Management, L.P., its investment  
manager

By: Apollo Capital Management GP, LLC, its general  
partner

By:  /s/ Maurice Amsellem

Name: Maurice Amsellem

Title: Authorized Signatory

---

**MIDCAP FUNDING III TRUST**

as a Lender

By: Apollo Capital Management, L.P., its investment  
manager

By: Apollo Capital Management GP, LLC, its general  
partner

By: /s/ Maurice Amsellem

Name: Maurice Amsellem

Title: Authorized Signatory



---

**MIDCAP FUNDING XIII TRUST**

as a Lender

By: Apollo Capital Management, L.P., its investment  
manager

By: Apollo Capital Management GP, LLC, its general  
partner

By:       /s/ Maurice Amsellem      

Name: Maurice Amsellem

Title: Authorized Signatory

---

**MIDCAP FUNDING IV TRUST**

as a Lender

By: Apollo Capital Management, L.P., its investment manager

By: Apollo Capital Management GP, LLC, its general partner

By:       /s/ Maurice Amsellem      

Name: Maurice Amsellem

Title: Authorized Signatory

---

**FLEXPOINT MCLS SPV LLC,**  
as a Lender

By: /s/ Daniel Edelman

Name: Daniel Edelman

Title: Vice President

**COMMITMENTS  
AND AGGREGATE EXPOSURE PERCENTAGES**

**INITIAL TERM COMMITMENTS; DELAYED DRAW TERM LOAN**

<u>Lender</u>	<u>Initial Term Commitments</u>	<u>Initial Term Percentage</u>
Silicon Valley Bank	\$20,000,000.00	50.0000000000%
MidCap Funding XIII Trust	\$1,000,000.00	2.5000000000%
Midcap Financial Trust	\$17,333,333.33	43.3333333333%
Flexpoint MCLS Holdings LLC	\$1,666,666.67	4.1666666667%
<b>Total</b>	<b>\$40,000,000.00</b>	<b>100.0000000000%</b>

<u>Lender</u>	<u>Delayed Draw Term Loan Tranche 1 Commitments</u>	<u>Delayed Draw Term Loan Tranche 1 Percentage</u>
Silicon Valley Bank	\$5,000,000.00	50.0000000000%
Midcap Financial Trust	\$4,583,333.33	45.8333333333%
Flexpoint MCLS Holdings LLC	\$416,666.67	4.1666666667%
<b>Total</b>	<b>\$10,000,000.00</b>	<b>100.0000000000%</b>

<u>Lender</u>	<u>Delayed Draw Term Loan Tranche 2 Commitments</u>	<u>Delayed Draw Term Loan Tranche 2 Percentage</u>
Silicon Valley Bank	\$5,000,000.00	50.0000000000%
Midcap Financial Trust	\$4,583,333.33	45.8333333333%
Flexpoint MCLS Holdings LLC	\$416,666.67	4.1666666667%
<b>Total</b>	<b>\$10,000,000.00</b>	<b>100.0000000000%</b>

<sup>1</sup> To be updated

## REVOLVING COMMITMENTS

<u>Lender</u>	<u>Revolving Commitment</u>	<u>Revolving Percentage</u>
Silicon Valley Bank	\$20,000,000.00	50.000000000000%
Midcap Financial Funding IV Trust	\$20,000,000.00	50.000000000000%
<b>Total</b>	<b>\$40,000,000.00</b>	<b>100.000000000000%</b>

## L/C COMMITMENTS

(which is a sublimit of, and not in addition to, the Revolving Commitments)

<u>Lender</u>	<u>L/C Commitments</u>	<u>L/C Percentage</u>
Silicon Valley Bank	\$1,250,000.00	50.000000000000%
Midcap Financial Funding IV Trust	\$1,250,000.00	50.000000000000%
<b>Total</b>	<b>\$2,500,000.00</b>	<b>100.000000000000%</b>

## SWINGLINE COMMITMENT

(which is a sublimit of, and not in addition to, the Revolving Commitments)

<u>Lender</u>	<u>Swingline Commitment</u>	<u>Exposure Percentage</u>
Silicon Valley Bank	\$5,000,000.00	100.000000000000%
<b>Total</b>	<b>\$5,000,000.00</b>	<b>100.000000000000%</b>